Lanicemine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Lanicemine
Systematic (IUPAC) name
(1S)-1-Phenyl-2-pyridin-2-ylethanamine
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
CAS number 153322-05-5
ATC code None
PubChem CID 9794203
Chemical data
Formula C13H14N2 
Mol. mass 198.26 g/mol

Lanicemine (AZD6765) is an NMDA antagonist developed by AstraZeneca,[1] which is being studied for the treatment of major depression. It was originally developed as a neuroprotective agent, but was redeveloped as an antidepressant following the observation that the anesthetic drug ketamine has potent antidepressant effects, but also has hallucinogenic side effects which make it unsuitable for use as an antidepressant in most circumstances. Lanicemine is a low-trapping NMDA receptor blocker which has been found in human trials to have similar rapid-acting antidepressant effects to ketamine, but with little or no psychotomimetic side effects.[2]

See also [edit]

References [edit]

  1. ^ US 6518432, Melvyn E. Giles, "Process", issued Feb 11, 2003 
  2. ^ Zarate, C. A.; Mathews, D.; Ibrahim, L.; Chaves, J. F.; Marquardt, C.; Ukoh, I.; Jolkovsky, L.; Brutsche, N. E. et al. (2012). "A Randomized Trial of a Low-Trapping Nonselective N-Methyl-D-Aspartate Channel Blocker in Major Depression". Biological Psychiatry. doi:10.1016/j.biopsych.2012.10.019. PMID 23206319.   edit


Retrieved from "http://en.wikipedia.org/w/index.php?title=Lanicemine&oldid=533708314"